SYNERGY™

Everolimus-Eluting Platinum Chromium Coronary Stent System

EVOLVE Short DAPT

3-month DAPT in High Bleeding Risk (HBR) patients undergoing PCI with the SYNERGY BP-DES

 

 

Studies the safety of discontinuing DAPT at 3-months in this HBR patient population using the SYNERGY BP-DES.

US Short DAPT Data Now Available
 

Trial Design

  • Prospective, multicenter, single-arm trial
  • 2,009 patients with significant bleeding risks at 110 global sites
  • Primary endpoint data collected from 1,487 patients eligible to discontinue DAPT at 3-months.
 

Clinical Outcomes at 12-months Post-DAPT Discontinuation

 
0.3% ST WITH 3-MONTH DAPT
SYNERGY BP-DES demonstrated low stent thrombosis in the 12-months following 3-month DAPT discontinuation
 
 
03-MONTH DAPT NON-INFERIOR TO 12-MONTH DAPT
Studies the safety of SYNERGY BP-DES with 3-month DAPT in this high bleeding risk population
 *The control for the Death/MI Endpoint is comprised of HBR subjects from HCRI DAPT Study and Promus Element post-approval studies that meet the EVOLVE Short DAPT criteria.
 

 
Clinical Outcomes

Clinical Outcomes

Outstanding evidence across trials

Button
Real-World Studies

Real-World Studies

Low event rates in real-world studies

Button
Early Healing

Early Healing

Advanced design for optimal healing

Button
Top